External PhD candidate Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- holleman@eshpm.eur.nl
More information
‹ Back to overview
Profile
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- Marscha Holleman, Carin Groot, S Goodall & Naomi Linden (2019) - Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data - Value in Health, 22, 322-331 - doi: 10.1016/j.jval.2018.08.007
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- Marscha Holleman, Carin Groot, S Goodall & Naomi Linden (2019) - Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data - Value in Health, 22, 322-331 - doi: 10.1016/j.jval.2018.08.007
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
- Marscha Holleman, H van Tinteren, HJM Groen, Maiwenn Al & Carin Groot (2019) - First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis - OncoTargets and Therapy, 12, 1413-1421 - doi: 10.2147/ott.S189438
- Marscha Holleman, Carin Groot, S Goodall & Naomi Linden (2019) - Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data - Value in Health, 22, 322-331 - doi: 10.1016/j.jval.2018.08.007
- Marscha Holleman, Maiwenn Al, Remziye Zaim, HJM Groen & Carin Groot (2019) - Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations - The European Journal Of Health Economics, 21, 153-164 - doi: 10.1007/s10198-019-01117-3
Master Thesis HE
- Year
- 2020
- Year Level
- master, master
- Course Code
- GW4592M
Afstudeerproject
- Level
- bachelor 3
- Year
- 2020
- Year Level
- bachelor 3
- Course Code
- GW310
Master Thesis HEPL
- Level
- master
- Year
- 2020
- Year Level
- master
- Course Code
- GW4555M
Advanced Health Economic Modelling
- Year
- 2020
- Year Level
- master, master, master
- Course Code
- GW4563M
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year
- 2020
- Year Level
- master
- Course Code
- GW4587M
Master Thesis HE
- Year
- 2020
- Year Level
- master, master
- Course Code
- GW4592M
Afstudeerproject
- Level
- bachelor 3
- Year
- 2020
- Year Level
- bachelor 3
- Course Code
- GW310
Master Thesis HEPL
- Level
- master
- Year
- 2020
- Year Level
- master
- Course Code
- GW4555M
Advanced Health Economic Modelling
- Year
- 2020
- Year Level
- master, master, master
- Course Code
- GW4563M
Advanced Health Economic Modelling EuHEM
- Level
- master
- Year
- 2020
- Year Level
- master
- Course Code
- GW4587M